Blair Watkins
Family · Wichita, KSNPI 1457972622
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,110 and has fallen 90.0% since, to $111 in 2024.
Across 152 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$341
- Vanda Pharmaceuticals Inc.$287
- Sunovion Pharmaceuticals Inc.$270
- Johnson & Johnson$249
- AbbVie$243
- Otsuka America Pharmaceutical, Inc.$152
- plus $970 from 15 others
What the payments were for
- Food & beverage$2,46298%
- Education$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $341 |
| Vanda Pharmaceuticals Inc. | 13 | $287 |
| Sunovion Pharmaceuticals Inc. | 17 | $270 |
| Johnson & Johnson | 11 | $249 |
| AbbVie | 15 | $243 |
| Otsuka America Pharmaceutical, Inc. | 11 | $152 |
| Alkermes, Inc. | 10 | $150 |
| Teva Pharmaceuticals USA, Inc. | 6 | $127 |
| Neurocrine Biosciences, Inc. | 10 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $119 |
| Lundbeck LLC | 6 | $106 |
| Supernus Pharmaceuticals, Inc. | 6 | $88 |
| Ironshore Pharmaceuticals Inc. | 3 | $62 |
| Indivior Inc. | 3 | $59 |
| Eisai Inc. | 2 | $34 |
| Corium, LLC | 2 | $24 |
| Merck | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $16 |
| Neos Therapeutics, LP | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$100
How this compares
$2,513 in reported general payments places this provider in the 85th percentile of 1,579 family providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 16 | $82 |
Paid to pharmacies, not to this prescriber.
Other family in Wichita
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Mary GonzalesWichita$87K
- Mary GarciaWichita$24K
- Jennifer NeelWichita$15K
- Amanda AstWichita$9K
- Jennifer MartinWichita$8K
- Lauren CoteWichita$7K
- Mimi TranWichita$6K
- Kara NabboutWichita$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.